In a report released today, Alex Arfaei from BMO Capital maintained a Hold rating on Elanco Animal Health Inc (ELAN), with a price target of $32. The company’s shares opened today at $31.10, close to its 52-week low of $30.10.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.5% and a 70.5% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elanco Animal Health Inc with a $35.50 average price target, representing a 14.1% upside. In a report released yesterday, Credit Suisse also maintained a Hold rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37.61 and a one-year low of $30.10. Currently, Elanco Animal Health Inc has an average volume of 2.11M.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELAN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It operates through the following categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.
